Soligenix, Inc.

[Available On-Demand]
We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Ticker:
SNGX
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
SGX301 for Cutaneous T-Cell Lymphoma (CTCL)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & CEO
Soligenix, Inc.